Apogee Therapeutics, Inc.
APGE
$68.50
$1.732.59%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 70.88M | 66.92M | 62.80M | 56.25M | 49.01M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 285.60M | 283.42M | 270.83M | 241.79M | 216.87M |
| Operating Income | -285.60M | -283.42M | -270.83M | -241.79M | -216.87M |
| Income Before Tax | -255.57M | -253.44M | -237.50M | -205.29M | -182.13M |
| Income Tax Expenses | 278.00K | 234.00K | 173.00K | 101.00K | 18.00K |
| Earnings from Continuing Operations | -255.84 | -253.67 | -237.67 | -205.39 | -182.15 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -255.84M | -253.67M | -237.67M | -205.39M | -182.15M |
| EBIT | -285.60M | -283.42M | -270.83M | -241.79M | -216.87M |
| EBITDA | -284.18M | -282.33M | -270.10M | -241.42M | -216.68M |
| EPS Basic | -4.22 | -4.36 | -4.12 | -3.59 | -3.28 |
| Normalized Basic EPS | -2.63 | -2.72 | -2.57 | -2.24 | -2.05 |
| EPS Diluted | -4.22 | -4.36 | -4.12 | -3.59 | -3.28 |
| Normalized Diluted EPS | -2.63 | -2.72 | -2.57 | -2.24 | -2.05 |
| Average Basic Shares Outstanding | 242.76M | 232.65M | 230.67M | 228.76M | 220.75M |
| Average Diluted Shares Outstanding | 242.76M | 232.65M | 230.67M | 228.76M | 220.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |